Company
Agenus
Agenus is a biopharmaceutical company developing immunotherapies designed to activate the immune system to recognize and eliminate cancer. The company's lead program, botensilimab plus balstilimab (BOT+BAL), is in clinical trials for colorectal cancer, merkel cell carcinoma, and sarcoma. Agenus aims to reduce patient reliance on chemotherapy, radiation, and surgery.
Agenus is a publicly traded company operating in the biotechnology sector, based in the United States. It trades on the Nasdaq under the ticker AGEN. Leadership tracked by CEOInsider includes Garo H. Armen (CEO).
Leadership
Current
Recent developments
AI summary of recent coverageRecent coverage has focused on Agenus leadership and corporate actions, including the grant of over 1.9 million performance-based stock options to CEO Garo Armen at a per-share price of $7.78, as well as his compensation through company shares. Coverage has also highlighted the company's clinical development activities, including the discontinuation of its Phase 3 BATTMAN trial in metastatic colorectal cancer and the company's first quarter 2026 financial results and ongoing program execution.
Summarized from the headlines in the sidebar; see each source for the full story.